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Abstract
 
Dietary methionine is mainly metabolized in the liver where it is converted into 
 
S
 
-adenosylmethionine (AdoMet), the main biologic
methyl donor. This reaction is catalyzed by methionine adenosyltransferase I/III (MAT I/III), the product of 
 
MAT1A
 
 gene, which is ex-
clusively expressed in this organ. It was first observed that serum methionine levels were elevated in experimental models of liver damage
and in liver cirrhosis in human beings. Results of further studies showed that this pathological alteration was due to reduced 
 
MAT1A
 
 gene
expression and MAT I/III enzyme inactivation associated with liver injury. Synthesis of AdoMet is essential to all cells in the organism,
but it is in the liver where most of the methylation reactions take place. The central role played by AdoMet in cellular function, together
with the observation that AdoMet administration reduces liver damage caused by different agents and improves survival of alcohol-
dependent patients with cirrhosis, led us to propose that alterations in methionine metabolism could play a role in the onset of liver dis-
ease and not just be a consequence of it. In the present work, we review the recent findings that support this hypothesis and highlight the
mechanisms behind the hepatoprotective role of AdoMet. © 2002 Elsevier Science Inc. All rights reserved.
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1. Overview
 
Methionine is one of the nine essential amino acids for
mammals. In addition to its incorporation in proteins, me-
thionine is a precursor of 
 
S
 
-adenosylmethionine (AdoMet).
In this reaction, the adenosyl moiety of ATP is transferred
to methionine, a process catalyzed by methionine adenosyl-
transferase (MAT) (Finkelstein, 1990). In the liver, MAT is
the product of 
 
MAT1A
 
 gene, which encodes a catalytic sub-
unit (
 

 
1
 
) that organizes into dimers (MAT III) and tetramers
(MAT I) (Kotb et al., 1997). AdoMet is the methyl donor
for essentially all known methylation reactions. In addition,
AdoMet provides the propylamine group for the synthesis
of polyamines and, in the liver, participates in the synthesis
of glutathione (GSH) through the transsulfuration pathway
(Finkelstein, 1990). Synthesis and metabolism of AdoMet
take place mainly in the liver, where up to 85% of methyla-
tion reactions and almost 50% of methionine metabolism
occur (Mudd & Poole, 1975). Other cell types express a dif-
ferent MAT gene, namely 
 
MAT2A
 
, which codes for the cat-
alytic subunit 
 

 
2
 
 that associates to form MAT II (Kotb &
Geller, 1993; Kotb et al., 1997). The kinetic and regulatory
properties of MAT I/III and MAT II are different. The ex-
pression of MAT I/III results in elevated cellular levels of
AdoMet for a wide range of physiological concentrations of
methionine, whereas MAT II is inhibited by micromolar
concentrations of AdoMet (Kotb & Geller, 1993; Mato et
al., 2001). The inhibition by AdoMet of MAT II activity
seems to be mediated by a regulatory subunit (
 

 
), which is
the product of 
 
MAT2B
 
 gene (LeGros et al., 2000). In the fe-
tal hepatocyte 
 
MAT1A
 
 is not expressed, whereas 
 
MAT2A
 
 is
actively transcribed. This pattern of expression is rapidly
switched after birth (Gil et al., 1996). Interestingly, when
the adult hepatocyte proliferates, as occurs after partial
hepatectomy, 
 
MAT2A
 
 expression is induced (Huang et al.,
1998; Latasa et al., 2001). The fetal pattern of MAT gene
expression is recovered on malignant transformation of the
liver: 
 
MAT1A
 
 expression is silenced and 
 
MAT2A
 
 is induced
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(Avila et al., 2000; Cai et al., 1996). This switch in MAT
gene expression has been suggested to provide the trans-
formed cell with a proliferative advantage (Cai et al., 1998).
Alterations in liver methionine metabolism have been as-
sociated with liver damage for more than 50 years (Kinsell
et al., 1947). Serum methionine levels are elevated in pa-
tients with alcoholic liver cirrhosis, and these patients dis-
play abnormal methionine clearance after an oral load of
this amino acid and delayed sulfate excretion (Avila et al.,
2000; Horowitz et al., 1981; Marchesini et al., 1992). Simi-
larly, in experimental models of liver damage, such as in
ethanol- and CCl
 
4
 
-induced liver injury, impairment in me-
thionine metabolism has been reported (Mato et al., 1997).
The mechanisms behind this alteration in methionine me-
tabolism began to be understood when it was observed that
patients with cirrhosis had reduced (50%) liver MAT activ-
ity as compared with findings for healthy controls (Cabrero
et al., 1988; Martín-Duce et al., 1988). These observations
were also made in various experimental models of liver dis-
ease, including in ethanol- and CCl
 
4
 
-treated rats and etha-
nol-fed baboons (Barak et al., 1987; Lieber et al., 1990; Lu
et al., 2000; Trimble et al., 1993; Varela-Moreiras et al.,
1995). Impairment in MAT activity compromises cellular
AdoMet synthesis, and this situation may have an impact on
many essential metabolic pathways in the liver in which
AdoMet participates. In fact, it has been observed that alter-
ations in homocysteine, carnitine, and phosphatidylethano-
lamine metabolism and DNA methylation develop in pa-
tients with cirrhosis and in experimental models of liver
damage (Avila et al., 2000; Krahenbuhl, 1996; Krahenbuhl
et al., 2000; Lieber et al., 1990, 1994; Mirpuri et al., 2002;
Varela-Moreiras et al., 1995). These alterations are likely to
influence the development of the disease. This view is sup-
ported in part by the protective effect of AdoMet (see dis-
cussion later) and AdoMet-dependent metabolites such as
phosphatidylcholine (Lieber, 1999a; Lieber et al., 1990,
1994; Navder et al., 1997) in experimental models of liver
damage and in patients with cirrhosis. It was subsequently
observed that MAT I/III activity was dependent on the re-
dox status of the cell, and that the prooxidant conditions that
developed in the cirrhotic liver could be behind the inhibi-
tion of MAT I/III (Lieber, 1997). Experimental evidence for
this was obtained when MAT I/III activity was measured in
rat liver after administration of butionine sulfoximine
(BSO), an inhibitor of GSH synthesis, and a reduction in
MAT I/III activity was observed (Corrales et al., 1991). In
addition, the administration of GSH–ethyl ester, which is
hydrolyzed intracellularly to provide GSH, prevented the
reduction in GSH levels and the inactivation of MAT I/III
by BSO treatment (Corrales et al., 1992).
The molecular mechanism responsible for MAT I/III in-
activation by free radicals has been characterized recently.
Rat MAT I/III contains 10 cysteine residues and thus is very
sensitive to thiol group modification (Mato et al., 2001).
Nevertheless, functional interaction with reactive oxygen
species seems to occur at a specific cysteine residue located
at position 121; the oxidation of this cysteine residue would
render the enzyme inactive (Sánchez-Góngora et al., 1997).
This observation is based on site-directed mutagenesis stud-
ies, in which all 10 cysteine residues were individually
changed by serines. All individual mutants were sensitive to
inactivation by oxygen free radicals, with the exception of
cysteine 121 mutant, which produced an enzyme that re-
tained its catalytic activity but that was resistant to inhibi-
tion by reactive oxygen species (Sánchez-Góngora et al.,
1997). Hence, this residue could represent a regulatory
switch for MAT I/III, sensitive to environmental changes in
the redox status of the hepatocyte. Interestingly, cysteine
121 is specific to human, rat, and mouse liver MAT and
MAT I/III and is not present in MAT II; hence this mecha-
nism of regulation would be restricted to the liver parenchy-
mal cell. Similarly, MAT I/III can be inactivated by nitric
oxide (NO) through the interaction of this free radical with
the same cysteine residue at position 121, resulting in the
 
S
 
-nitrosylation of the thiol group (Avila et al., 1997; Ruiz et
al., 1998). This has been demonstrated both in vitro with the
purified rat liver enzyme and in vivo when rats were admin-
istered bacterial lipopolysaccharide (LPS), or in cultured rat
hepatocytes under hypoxia, conditions known to trigger the
synthesis of NO in the liver (Avila et al., 1997, 1998; Ruiz
et al., 1998). Interestingly, MAT I/III inactivation by NO
was reversible by incubation of the purified enzyme with
thiol-reducing agents such as GSH (Avila et al., 1997) and
was dependent on the hepatic levels of GSH in vivo (Cor-
rales et al., 1999). Taken together these observations may be
of clinical relevance because the development of oxidative
stress in the liver, endotoxemia, and deficient oxygen sup-
ply to the pericentral region of the hepatic parenchyma are
well recognized in individuals who are chronically depen-
dent on alcohol (Avila et al., 1998; Bjarnason et al., 1984).
Besides MAT I/III activity, the expression of 
 
MAT1A
 
 is
also compromised in the diseased liver. This has been ob-
served in the experimental model of CCl
 
4
 
-induced liver in-
jury in rats (Torres et al., 2000) and in the liver of patients
with cirrhosis of different causes (alcoholic and viral cirrho-
sis) (Avila et al., 2000). The oxidative stress that develops in
these experimental models and in pathological conditions
seems not to be related directly to the reported alterations in
 
MAT1A
 
 gene expression. This is based on both the absence of
oxidant-sensitive response elements in 
 
MAT1A
 
 promoter
(Mato et al., 2001) and the direct experimental evidence ob-
tained in cultured rat hepatocytes treated with oxidative
stress–promoting agents (Carretero et al., 2001). Interest-
ingly, the reduction in 
 
MAT1A
 
 mRNA levels was accompa-
nied by the hypermethylation of its promoter, a covalent
modification of DNA that plays a role in the silencing of gene
expression and that could be involved in the above-men-
tioned loss of 
 
MAT1A
 
 expression on malignant transforma-
tion of the liver (Avila et al., 2000; Torres et al., 2000).
The main consequence of all these defects in MAT I/III
expression and activity is the impaired synthesis of AdoMet
in alcoholic liver disease, which is a clear example of how
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ethanol may interfere with the activation of an essential nu-
trient (Holm et al., 1999; Lieber, 1999b). The relevance for
the liver of a deficient supply of AdoMet may be inferred
from the key role played by this metabolite in cellular func-
tion. The most extreme example of the essential role of
preserving adequate hepatic AdoMet levels would be the
observation that administration of methionine–choline-defi-
cient diets induced hepatocyte de-differentiation and the de-
velopment of liver tumors in rodents (Newberne & Rogers,
1986; Wainfan et al., 1989). Thus it has been proposed that
reduced AdoMet availability plays an important role in the
development of liver damage and that AdoMet supplemen-
tation could have hepatoprotective effects and a therapeutic
value devoid of unwanted side effects (Chawla et al., 1990;
Lieber, 1999b). Compelling evidence supporting this view
has been provided by numerous experimental models of
liver damage, both in rodents and in non-human primates, in
which the administration of AdoMet partially restored liver
function, including prevention of liver steatosis, fibrosis,
and chemically induced hepatocarcinogenesis (Chawla et
al., 1990; Garcea et al., 1989; Mato et al., 1997; Pascale et
al., 1992). There are also studies with human subjects in
which AdoMet administration to patients suffering from
cholestasis induced by chronic liver disease resulted in the
improvement of serum markers of cholestasis (Frezza et al.,
1990). AdoMet treatment also has been shown to be bene-
ficial in severe cholestasis of pregnancy (Frezza, 1993).
However, the best evidence of the therapeutic potential of
AdoMet was provided recently by a long-term randomized,
placebo-controlled, double-blind, multicenter clinical trial
of AdoMet (1.2 g/day, orally, over a 24-month period) in
123 patients with alcoholic liver cirrhosis, in whom it im-
proved survival or delayed the need for liver transplantation
(Mato et al., 1999).
The mechanisms through which AdoMet exerts its
hepatoprotective actions are likely to be multifaceted, given
the numerous reactions in which this molecule participates,
including phospholipid, protein, and DNA methylation.
Counteracting the oxidative stress developed with ethanol
metabolism or viral infection may be one key mechanism
(Mato et al., 1997). As previously mentioned, AdoMet is a
precursor for cysteine, one of the three amino acids of GSH,
the major biologic antioxidant molecule. It has been shown
in patients with alcoholic liver disease that administration
of AdoMet (1.2 g/day, orally) for 6 months significantly
increased hepatic GSH (Vendemiale et al., 1989). Similar
observations have been made in experimental models of
ethanol- and CCl
 
4
 
-induced liver injury, in which AdoMet
treatment improved hepatic GSH and attenuated hepatocel-
lular injury (Corrales et al., 1992; García-Ruiz et al., 1995;
Lieber et al., 1990). Among the beneficial effects of im-
proving GSH levels in the hepatocyte is the restoration of
MAT I/III activity and thus of the ability of the cell to con-
vert dietary methionine into AdoMet, therefore preserving
the essential metabolic flow of methyl groups (Corrales et
al., 1992; Finkelstein, 1990).
However, AdoMet seems to have even more profound
effects on cell function. We have shown recently that
changes in the intracellular concentrations of this molecule
can modulate hepatocyte gene expression (García-Trevijano
et al., 2000). In the experimental model of cultured primary
rat hepatocytes, the expression of liver-specific genes (e.g.,
 
MAT1A
 
) is progressively lost, whereas that of some non-
liver-specific genes (including 
 
MAT2A
 
) is increased, re-
flecting a certain degree of de-differentiation (García-Trevi-
jano et al., 2000; Schuetz et al., 1988). Addition of AdoMet
to cultured hepatocytes potently stimulated the expression
of 
 
MAT1A
 
 while it simultaneously prevented induction of the
expression of the non-liver-specific 
 
MAT2A
 
 gene (García-
Trevijano et al., 2000). Moreover, AdoMet treatment of cul-
tured rat hepatocytes reversed the negative effect of certain
hepatotoxins such as aromatic aryl hydrocarbons on the ex-
pression of 
 
MAT1A
 
 (Carretero et al., 2001). These observa-
tions suggested to us that AdoMet could play a role in the
preservation of the differentiated pattern of gene expression
in the liver and that the progressive loss in the AdoMet-syn-
thesizing ability of the chronically injured liver could have a
negative impact on gene expression independent of DNA
methylation.
The essential functions of AdoMet in the liver seem to
transcend its purely metabolic role as a methyl-group donor
in transmethylation reactions. Evidence is accumulating in-
dicating that this molecule can indeed modulate the re-
sponses of the hepatocyte to growth factors and cytokines,
such as hepatocyte growth factor (HGF) and tumor necrosis
factor-
 

 
 (TNF-
 

 
). In these regards, we have shown recently
that the proliferative response of cultured hepatocytes to
HGF depends on the intracellular levels of AdoMet, sug-
gesting novel implications for this molecule in the liver re-
generative response (Latasa et al., 2001). These observa-
tions may also be of relevance regarding the antineoplastic
effects of AdoMet in chemically induced hepatocarcinoma
(Garcea et al., 1989; Pascale et al., 1992). Similarly, activation
of the transcription factor nuclear factor-kappa B (NF-
 

 
B)
and induction of NO synthase 2 by proinflammatory cyto-
kines, including TNF-
 

 
, were also modulated in vivo and in
vitro by AdoMet treatment (Majano et al., 2001).
All evidence summarized so far supports the notion of
the likely involvement of impaired AdoMet synthesis in the
development of liver injury. However, definitive proof was
lacking until a 
 
MAT1A
 
 knockout mouse deficient in hepatic
MAT (MATO mouse) became available (Lu et al., 2001). In
this model of chronic hepatic AdoMet reduction (70% less
hepatic AdoMet levels than in wild-type mice), marked he-
patic alterations were evident by 3 months of age, including
hepatic hyperplasia and a pronounced tendency for steatosis
to develop after feeding of a choline-deficient diet (Lu et al.,
2001). Genomic profiling of these animals versus wild-type
mice by microarray analysis showed changes in a substan-
tial number of genes involved in cell proliferation, differen-
tiation, and acute phase response (Lu et al., 2001). In addi-
tion, 3-month-old MATO mice are much more sensitive to
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CCl
 
4
 
-induced liver damage, as determined histologically
and by serum levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) (unpublished observa-
tions, J. M. Mato, 2001). At 8 months of age, steatohepatitis
developed in MATO mice in the absence of any liver-dam-
aging treatment (Lu et al., 2001). These results clearly attest
to the contribution of chronic deficiency in hepatic AdoMet
synthesis, as evidenced in patients with liver cirrhosis, in
the pathogenesis of liver injury and also confirm a role for
AdoMet in the preservation of the quiescent and differenti-
ated status of the hepatocyte.
 
2. Future directions
 
Future challenges in the understanding of AdoMet func-
tions in liver biology and pathophysiology will include is-
sues such as the delineation of the precise molecular events
through which this compound regulates gene expression.
Experiments carried out in cultured hepatic cell models will
help to identify the subcellular location and targets of
AdoMet interactions. It is also of interest to know whether
such effects would be mediated through a methylation reac-
tion or through binding of AdoMet to proteins in the ab-
sence of methyl-group transfer. Additionally, use of MATO
mice will be instrumental in furthering our knowledge of
the consequences of chronic hepatic AdoMet deficiency.
Extensive genomic profiling and proteomic analysis will
help to identify novel targets for AdoMet, illustrating at the
same time the early molecular changes that precede and ac-
company the development of steatohepatitis. As suggested
by the proliferative disorders observed in MATO mice, it
will be important to know whether these animals display en-
hanced risk for the development of hepatocarcinoma.
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